Kotlov Mikhail MD is categorized under Internal Medicine Practitioners in Hackensack, NJ and active since 2010.
Kotlov Mikhail MD was established in 2010, and today employs 1 to 4, earning $500.000 to $999.999 per year. This is a Internal Medicine Practitioners business, which does work in the B2C market, and is classified as a Internal Medicine Practitioners, under code number 6211110 by the NAICS.
If you are seeking more information, feel free to contact Mikhail Kotlov at the company’s single location by writing to 20 Prospect Avenue # 709, Hackensack, New Jersey NJ 07601 or by phoning (201) 678-0300. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
Business Name: | Kotlov Mikhail MD |
Contact Person: | Mikhail Kotlov |
Address: | 20 Prospect Avenue # 709, Hackensack, New Jersey 07601 |
Phone Number: | (201) 678-0300 |
Website Address: | bergenrenal.com |
Annual Revenue (USD): | $500.000 to $999.999 |
Founded: | 2010 |
Location Type: | Single Location |
Employee Number: | 1 to 4 |
Business Type: | B2C (Business to Consumer) |
Business Category: | Internal Medicine Practitioners |
SIC Code: | 8011 |
NAICS Code: | 6211110 |
Share This Business: |
Kotlov Mikhail MD was started in 2010 to provide professional Internal Medicine Practitioners under the SIC code 8011 and NAICS code 6211110. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $500.000 to $999.999 per annum.
Feel free to contact Mikhail Kotlov for inquiries that concern Kotlov Mikhail MD by calling the company number (201) 678-0300, as your correspondence is most welcome. Additionally, the physical location of the single location of Kotlov Mikhail MD can be found at the coordinates 40.88375,-74.05802 as well as the street address 20 Prospect Avenue # 709 in Hackensack, New Jersey 07601.
For its online presence, you may visit Kotlov Mikhail MD’s website at bergenrenal.com and engage with its social media outlets through on Twitter and on Facebook.